What is the official name of Venetoclax/Venetoclax in the country?

Venetoclax/Venetoclax, an anti-cancer drug that has attracted widespread attention around the world, has been officially launched in the domestic market as Venetoclax tablets (trade name: VENCLEXTA). However, it should be noted that although the original drug has been launched in China, as of 2024, the domestic generic version has not yet been launched.

Venacla was known as ABT-199 during the development phase. This drug is an oral B-cell lymphoma factor-2 (BCL-2) inhibitor that can precisely inhibit the function of BCL-2. Through this mechanism, venetoclax can restore the response of tumor cells to apoptotic signals, thereby promoting tumor cells to undergo apoptosis.

In the treatment of chronic lymphocytic leukemia (CLL), venetoclax has been approved in the United States and other countries and regions for the treatment of multiple indications. It can not only be used as a single-agent treatment for CLL patients with 17p deletion mutations and have received at least one previous therapy, but can also be used in combination with other drugs such as Rituxan (rituximab) or Gazyva (octuzumab) to treat CLL patients at different stages and with different treatment histories.

In addition, venetoclax has also demonstrated significant efficacy in the treatment of acute myeloid leukemia (AML). It can be used in combination with a hypomethylating agent (such as azacitidine or decitabine) or low-dose cytarabine as a first-line treatment option, especially for newly diagnosed elderly AML patients aged 75 and above, or for adult AML patients who are not suitable for intensive induction chemotherapy due to other comorbidities.

In view of the special nature of the drug, patients must strictly follow the doctor's instructions when using venetoclax and clarify the drug's indications, usage and dosage, and potential adverse reactions to ensure the safety and effectiveness of the treatment process.